Image: artofthestate.co.uk
Dear GSK,
I am writing to you as I am confused regarding an ongoing Paxil [Seroxat] study currently underway from GlaxoSmithKline, Japan.
I refer you to The Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study) - http://clinicaltrials.gov/ct2/show/NCT00812812
As a matter of public record I would like either GlaxoSmithKline UK or GlaxoSmithKline Japan to explain why this study has been put in place. In other words, what is GlaxoSmithKline's motive behind this study?
I am bewildered why GlaxoSmithKline would wish to pursue testing the safety and efficacy of paroxetine in children when you have already deemed that paroxetine is not safe for children.
I strongly object to this clinical trial and I can see no beneficial reason why you are undertaking it. I also fear for those children taking part in the study.
I don't think I need to point you to the Paxil 329 studies, do I?
I am sure that you are aware who I am, your employees and lawyers representing you seem to spend an awful amount of time on my blog.
Regardless, of who I am and what I write about, I would like an answer in writing regarding your motives behind The Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
I have a genuine concern for the children taking part in this study and also question your motives behind such a program.
Sincerely,
Bob Fiddaman
Author of Seroxat Sufferers
Author of the book, The Evidence, However, Is Clear...The Seroxat Scandal
**Interested parties have been blind copied.
---
A reminder of what we are dealing with here.
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
